ReviewTrends in cancer2016
Actionable molecular biomarkers in primary brain tumors.
Review in Trends in cancer, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 1 synthesis or guideline pooled it.
- The potential role ofBioscience reports · 2018Pooled it
- Small Extracellular Vesicles Isolated from Serum May Serve as Signal-Enhancers for the Monitoring of CNS Tumors.International journal of molecular sciences · 2020Trial
- Brain Cancer: Molecular Alterations and Emerging Trends in Neuropharmacology.International journal of molecular sciences · 2026Review
- Artificial intelligence-based biomarkers for the diagnosis and treatment of neurological conditions: a narrative review.Molecular brain · 2026Review
- The development of a rapid patient-derived xenograft model to predict chemotherapeutic drug sensitivity/resistance in malignant glial tumors.Neuro-oncology · 2023Article
- Molecular marker testing and reporting completeness for adult-type diffuse gliomas in the United States.Neuro-oncology practice · 2023Article
- MMP-9 as Prognostic Marker for Brain Tumours: A Comparative Study on Serum-Derived Small Extracellular Vesicles.Cancers · 2023Article
- Unleashing the Mystery of a Treated Case of Medulloblastoma.The Indian journal of radiology & imaging · 2022Article
- Cathepsin F and Fibulin-1 as novel diagnostic biomarkers for brain metastasis of non-small cell lung cancer.British journal of cancer · 2022Article
- HOXC6 impacts epithelial-mesenchymal transition and the immune microenvironment through gene transcription in gliomas.Cancer cell international · 2022Article
- Imaging diagnosis and treatment selection for brain tumors in the era of molecular therapeutics.Cancer imaging : the official publication of the International Cancer Imaging Society · 2022Review
- ITGB2 as a prognostic indicator and a predictive marker for immunotherapy in gliomas.Cancer immunology, immunotherapy : CII · 2022Article
- mTORC1 promotes malignant large cell/anaplastic histology and is a targetable vulnerability in SHH-TP53 mutant medulloblastoma.JCI insight · 2021Article
- Lack of Benefit of Extending Temozolomide Treatment in Patients with High Vascular Glioblastoma with MethylatedCancers · 2021Article
- Upregulated Expression of Cancer-Derived Immunoglobulin G Is Associated With Progression in Glioma.Frontiers in oncology · 2021Article
- Effect of FAT1 gene expression on the prognosis of medulloblastoma in children: A protocol for systematic review and meta-analysis.Medicine · 2020Article
- Observational
- Review
- Quantitative MRI Biomarkers of Stereotactic Radiotherapy Outcome in Brain Metastasis.Scientific reports · 2019Article
- Discovery of predictive biomarkers in malignant gliomas.Neuro-oncology · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Recent genome-wide studies of malignancies of the central nervous system (CNS) have revolutionized our understanding of the biology of these tumors. This newly gained knowledge provides a wealth of opportunity for biomarker driven clinical research. To date, however, only few of the available molecular markers truly influence clinical decision-making and treatment. The most widely validated markers in neuro-oncology presently are: 1)
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.